BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

824 related articles for article (PubMed ID: 30795950)

  • 1. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
    Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
    Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
    Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
    Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
    Canfell K; Kim JJ; Brisson M; Keane A; Simms KT; Caruana M; Burger EA; Martin D; Nguyen DTN; Bénard É; Sy S; Regan C; Drolet M; Gingras G; Laprise JF; Torode J; Smith MA; Fidarova E; Trapani D; Bray F; Ilbawi A; Broutet N; Hutubessy R
    Lancet; 2020 Feb; 395(10224):591-603. PubMed ID: 32007142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
    Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
    Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the effect of HIV on cervical cancer elimination in South Africa: Comparative modelling of the impact of vaccination and screening.
    Boily MC; Barnabas RV; Rönn MM; Bayer CJ; van Schalkwyk C; Soni N; Rao DW; Staadegaard L; Liu G; Silhol R; Brisson M; Johnson LF; Bloem P; Gottlieb S; Broutet N; Dalal S
    EClinicalMedicine; 2022 Dec; 54():101754. PubMed ID: 36583170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of human papillomavirus screening with self-collection and digital registry support.
    Keane A; Ng CW; Simms KT; Nguyen D; Woo YL; Saville M; Canfell K
    Int J Cancer; 2021 Dec; 149(12):1997-2009. PubMed ID: 34363620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study.
    Xia C; Hu S; Xu X; Zhao X; Qiao Y; Broutet N; Canfell K; Hutubessy R; Zhao F
    Lancet Public Health; 2019 Sep; 4(9):e462-e472. PubMed ID: 31493843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Projected time to elimination of cervical cancer in the USA: a comparative modelling study.
    Burger EA; Smith MA; Killen J; Sy S; Simms KT; Canfell K; Kim JJ
    Lancet Public Health; 2020 Apr; 5(4):e213-e222. PubMed ID: 32057315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study.
    Man I; Georges D; de Carvalho TM; Ray Saraswati L; Bhandari P; Kataria I; Siddiqui M; Muwonge R; Lucas E; Berkhof J; Sankaranarayanan R; Bogaards JA; Basu P; Baussano I
    Lancet Oncol; 2022 Nov; 23(11):1419-1429. PubMed ID: 36174583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
    Castanon A; Landy R; Pesola F; Windridge P; Sasieni P
    Lancet Public Health; 2018 Jan; 3(1):e34-e43. PubMed ID: 29307386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.
    Hall MT; Smith MA; Simms KT; Barnabas R; Murray JM; Canfell K
    Int J Cancer; 2021 Jul; 149(2):297-306. PubMed ID: 33634857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis.
    Bruni L; Diaz M; Barrionuevo-Rosas L; Herrero R; Bray F; Bosch FX; de Sanjosé S; Castellsagué X
    Lancet Glob Health; 2016 Jul; 4(7):e453-63. PubMed ID: 27340003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards the global elimination of cervical cancer.
    Canfell K
    Papillomavirus Res; 2019 Dec; 8():100170. PubMed ID: 31176807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study.
    Simms KT; Hanley SJB; Smith MA; Keane A; Canfell K
    Lancet Public Health; 2020 Apr; 5(4):e223-e234. PubMed ID: 32057317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis.
    Bénard É; Drolet M; Laprise JF; Gingras G; Jit M; Boily MC; Bloem P; Brisson M
    Lancet Public Health; 2023 Oct; 8(10):e788-e799. PubMed ID: 37777288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
    Jit M; Brisson M; Portnoy A; Hutubessy R
    Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis.
    Bénard É; Drolet M; Laprise JF; Jit M; Prem K; Boily MC; Brisson M
    Lancet Glob Health; 2023 Jan; 11(1):e48-e58. PubMed ID: 36521952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative.
    Singh D; Vignat J; Lorenzoni V; Eslahi M; Ginsburg O; Lauby-Secretan B; Arbyn M; Basu P; Bray F; Vaccarella S
    Lancet Glob Health; 2023 Feb; 11(2):e197-e206. PubMed ID: 36528031
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 42.